Complicated Skin and Skin Structure Infections
CUBICIN 4 mg/kg should be administered over a 30-minute period by IV infusion in
0.9% sodium chloride injection once every 24 hours for 7 to 14 days. In Phase 1
and 2 clinical studies, CPK elevations appeared to be more frequent when CUBICIN
was dosed more frequently than once daily. Therefore, CUBICIN should not be
dosed more frequently than once a day.
Staphylococcus aureus Bloodstream Infections (Bacteremia), Including
Those with Right-Sided Endocarditis, Caused by Methicillin-Susceptible and
CUBICIN 6 mg/kg should be administered over a 30-minute period by IV infusion in
0.9% sodium chloride injection once every 24 hours for a minimum of 2 to 6
weeks. Duration of treatment should be based on the treating physician’s working
diagnosis. There are limited safety data for the use of CUBICIN for more than 28
days of therapy. In the Phase 3 study, there were a total of 14 patients who
were treated with CUBICIN for more than 28 days, 8 of whom were treated for 6
weeks or longer.
In Phase 1 and 2 clinical studies, CPK elevations appeared to be more frequent
when CUBICIN was dosed more frequently than once daily. Therefore, CUBICIN
should not be dosed more frequently than once a day.
Patients with Renal Impairment:
Daptomycin is eliminated primarily by the kidneys; therefore, a
modification of CUBICIN dosage is recommended for patients with CLCR <30
mL/min, including patients receiving hemodialysis or continuous
ambulatory peritoneal dialysis (CAPD). In patients
with renal impairment, both renal function and creatine phosphokinase
(CPK) should be monitored more frequently than once weekly.
Clearance method (package insert): CLCR,
creatinine clearance estimated using the Cockcroft-Gault equation with
actual body weight.
S. aureus Bloodstream
4 mg/kg once every 24 hours
6 mg/kg once every 24 hours
<30 mL/min, including
hemodialysis or CAPD
4 mg/kg once every 48 hours
6 mg/kg once every 48 hours
See above. When possible, CUBICIN should be administered
following the completion of hemodialysis on hemodialysis days
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read